MX2015014055A - Silicato de zirconio microporoso y diureticos para la reduccion de potasio y tratamiento de enfermedades renales cronicas y/o cardiacas cronicas. - Google Patents
Silicato de zirconio microporoso y diureticos para la reduccion de potasio y tratamiento de enfermedades renales cronicas y/o cardiacas cronicas.Info
- Publication number
- MX2015014055A MX2015014055A MX2015014055A MX2015014055A MX2015014055A MX 2015014055 A MX2015014055 A MX 2015014055A MX 2015014055 A MX2015014055 A MX 2015014055A MX 2015014055 A MX2015014055 A MX 2015014055A MX 2015014055 A MX2015014055 A MX 2015014055A
- Authority
- MX
- Mexico
- Prior art keywords
- chronic
- treatment
- heart disease
- diuretics
- zirconium silicate
- Prior art date
Links
- 230000001684 chronic effect Effects 0.000 title abstract 4
- 208000019622 heart disease Diseases 0.000 title abstract 3
- 239000002934 diuretic Substances 0.000 title abstract 2
- 229940030606 diuretics Drugs 0.000 title abstract 2
- GFQYVLUOOAAOGM-UHFFFAOYSA-N zirconium(iv) silicate Chemical compound [Zr+4].[O-][Si]([O-])([O-])[O-] GFQYVLUOOAAOGM-UHFFFAOYSA-N 0.000 title abstract 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 title 1
- 210000003734 kidney Anatomy 0.000 title 1
- 229910052700 potassium Inorganic materials 0.000 title 1
- 239000011591 potassium Substances 0.000 title 1
- 208000002682 Hyperkalemia Diseases 0.000 abstract 3
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 2
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 2
- 229960002478 aldosterone Drugs 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B39/00—Compounds having molecular sieve and base-exchange properties, e.g. crystalline zeolites; Their preparation; After-treatment, e.g. ion-exchange or dealumination
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Life Sciences & Earth Sciences (AREA)
- Geology (AREA)
- Materials Engineering (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361808897P | 2013-04-05 | 2013-04-05 | |
| US201361914362P | 2013-12-10 | 2013-12-10 | |
| US201461930331P | 2014-01-22 | 2014-01-22 | |
| PCT/US2014/032815 WO2014165670A1 (en) | 2013-04-05 | 2014-04-03 | Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015014055A true MX2015014055A (es) | 2015-12-15 |
Family
ID=51654632
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015014055A MX2015014055A (es) | 2013-04-05 | 2014-04-03 | Silicato de zirconio microporoso y diureticos para la reduccion de potasio y tratamiento de enfermedades renales cronicas y/o cardiacas cronicas. |
Country Status (21)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109106725A (zh) | 2011-02-11 | 2019-01-01 | Zs制药公司 | 用于治疗高钾血症的微孔性的硅酸锆 |
| US9592253B1 (en) * | 2015-10-14 | 2017-03-14 | ZS Pharma, Inc. | Extended use zirconium silicate compositions and methods of use thereof |
| CN114917247B (zh) * | 2022-05-18 | 2024-01-26 | 广东省疾病预防控制中心 | 纳米二氧化钛在防治肾损伤中的应用 |
| CN117776193A (zh) * | 2023-12-25 | 2024-03-29 | 杭州国瑞生物科技有限公司 | 一种环硅酸锆钠zs-9的制备方法及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9601398D0 (en) * | 1996-01-24 | 1996-03-27 | Piper Edwina M | Composition |
| US5888472A (en) | 1997-04-08 | 1999-03-30 | Uop Llc | Zirconium silicate molecular sieves and process using the same |
| US5891417A (en) | 1997-04-08 | 1999-04-06 | Uop Llc | Zirconium silicate and zirconium germanate molecular sieves and process using the same |
| US6099737A (en) | 1999-03-29 | 2000-08-08 | Uop Llc | Process for removing toxins from blood using zirconium metallate or titanium metallate compositions |
| US6332985B1 (en) | 1999-03-29 | 2001-12-25 | Uop Llc | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
| AU2000260501A1 (en) * | 2000-07-12 | 2002-01-21 | Uop Llc | Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions |
| US20040105895A1 (en) * | 2001-02-06 | 2004-06-03 | Ash Stephen R | Monovalent-selective cation exchangers as oral sorbent therapy |
| US6579460B1 (en) * | 2001-03-13 | 2003-06-17 | Uop Llc | Process and composition for removing toxins from bodily fluids |
| WO2010022381A1 (en) | 2008-08-22 | 2010-02-25 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| ES2939021T3 (es) * | 2008-08-22 | 2023-04-18 | Vifor Int Ltd | Composiciones que comprenden polímeros reticulados de intercambio catiónico y uso en el tratamiento de la hipercalemia |
| US20120070468A1 (en) * | 2010-09-16 | 2012-03-22 | Uop Llc | Removal of toxins from gastrointestinal fluids |
| CN109106725A (zh) | 2011-02-11 | 2019-01-01 | Zs制药公司 | 用于治疗高钾血症的微孔性的硅酸锆 |
| AU2013290141A1 (en) | 2012-07-11 | 2015-02-05 | Alvaro F. Guillem | Microporous zirconium silicate for the treatment of hyperkalemia in hypercalcemic patients and improved calcium-containing compositions for the treatment of hyperkalemia |
| CN104797263B (zh) * | 2012-10-22 | 2018-02-09 | Zs制药公司 | 用于治疗高钾血症的微孔硅酸锆 |
-
2014
- 2014-04-03 EP EP14779186.7A patent/EP2981272B1/en not_active Revoked
- 2014-04-03 WO PCT/US2014/032815 patent/WO2014165670A1/en not_active Ceased
- 2014-04-03 MX MX2015014055A patent/MX2015014055A/es unknown
- 2014-04-03 US US14/782,288 patent/US20160051584A1/en not_active Abandoned
- 2014-04-03 CA CA2908641A patent/CA2908641C/en active Active
- 2014-04-03 AU AU2014248081A patent/AU2014248081B2/en active Active
- 2014-04-03 PL PL14779186.7T patent/PL2981272T3/pl unknown
- 2014-04-03 KR KR1020157031787A patent/KR102308673B1/ko active Active
- 2014-04-03 JP JP2016506615A patent/JP6280636B2/ja active Active
- 2014-04-03 CN CN201480032064.8A patent/CN105473151B/zh active Active
- 2014-04-03 FI FIEP14779186.7T patent/FI2981272T3/fi active
- 2014-04-03 PT PT147791867T patent/PT2981272T/pt unknown
- 2014-04-03 BR BR112015025438-1A patent/BR112015025438B1/pt active IP Right Grant
- 2014-04-03 DK DK14779186.7T patent/DK2981272T3/da active
- 2014-04-03 ES ES14779186T patent/ES2943007T3/es active Active
- 2014-04-03 HU HUE14779186A patent/HUE061862T2/hu unknown
- 2014-04-03 US US14/244,446 patent/US20140302175A1/en not_active Abandoned
- 2014-04-07 TW TW103112757A patent/TW201521746A/zh unknown
-
2015
- 2015-10-02 CL CL2015002951A patent/CL2015002951A1/es unknown
- 2015-10-05 PH PH12015502301A patent/PH12015502301A1/en unknown
- 2015-10-06 IL IL241926A patent/IL241926B/en active IP Right Grant
- 2015-10-14 ZA ZA2015/07666A patent/ZA201507666B/en unknown
-
2018
- 2018-03-19 US US15/925,348 patent/US10695366B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2943007T3 (es) | 2023-06-08 |
| BR112015025438B1 (pt) | 2022-06-07 |
| CA2908641C (en) | 2022-10-18 |
| DK2981272T3 (da) | 2023-05-01 |
| WO2014165670A1 (en) | 2014-10-09 |
| CL2015002951A1 (es) | 2016-11-11 |
| JP6280636B2 (ja) | 2018-02-14 |
| EP2981272A4 (en) | 2016-12-07 |
| US20180271902A1 (en) | 2018-09-27 |
| KR102308673B1 (ko) | 2021-10-01 |
| EP2981272A1 (en) | 2016-02-10 |
| PL2981272T3 (pl) | 2023-05-29 |
| CN105473151B (zh) | 2018-09-18 |
| US20140302175A1 (en) | 2014-10-09 |
| CN105473151A (zh) | 2016-04-06 |
| CA2908641A1 (en) | 2014-10-09 |
| IL241926B (en) | 2020-10-29 |
| PT2981272T (pt) | 2023-05-03 |
| US20160051584A1 (en) | 2016-02-25 |
| PH12015502301A1 (en) | 2016-02-10 |
| TW201521746A (zh) | 2015-06-16 |
| FI2981272T3 (fi) | 2023-05-03 |
| AU2014248081B2 (en) | 2019-02-28 |
| BR112015025438A2 (pt) | 2017-07-18 |
| HK1221177A1 (en) | 2017-05-26 |
| HUE061862T2 (hu) | 2023-08-28 |
| KR20150140750A (ko) | 2015-12-16 |
| EP2981272B1 (en) | 2023-03-01 |
| JP2016515624A (ja) | 2016-05-30 |
| ZA201507666B (en) | 2019-09-25 |
| US10695366B2 (en) | 2020-06-30 |
| AU2014248081A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017010734A (es) | Terapia de combinacion con factores de coagulacion y anticuepos multiespecificos. | |
| EA033286B1 (ru) | Способ лечения или отсрочки развития хронической болезни почек | |
| TWD166502S (zh) | 機車 | |
| MX2015007751A (es) | Anticuerpos anti-gdf15. | |
| MX370903B (es) | Composiciones de ácido percarboxílico estables y sus usos. | |
| WO2014135987A3 (en) | Frequency optimization in ultrasound treatment | |
| PH12015502275A1 (en) | Therapuetic uses of empagliflozin | |
| IN2014KN02831A (cg-RX-API-DMAC7.html) | ||
| GB201411274D0 (en) | Improvements in and relating to neurostimulating devices for treating pain, improving function and other nervous system related conditions. | |
| MX2020010004A (es) | Composicion farmaceutica que comprende empagliflozina, metodos para tratamiento y sus usos. | |
| CA2947310C (en) | Microparticles for treating renal cell carcinoma | |
| FR3016371B1 (fr) | Levures modifiees pour utiliser le dioxyde de carbone | |
| WO2014159669A3 (en) | Aptamers that bind to il-6 and their use in treating or diagnosing il-6 mediated conditions | |
| HK1212713A1 (zh) | Vegfr1抗體的治療性用途 | |
| WO2014197835A3 (en) | Methods and compositions for the treatment of cancer | |
| MX2019013468A (es) | Metodos para tratar la enfermedad pulmonar obstructiva cronica usando benralizumab. | |
| PH12015502301A1 (en) | Microporous zirconium silicate and diuretics for the reduction of potassium and treatment of chronic kidney and/or chronic heart disease | |
| Gnendiger et al. | The infrared structure of QCD amplitudes and H→ gg in FDH and DRED | |
| EP3027049A4 (en) | Treatment of beverages to reduce the effects of noxious constituents | |
| IL236776A0 (en) | Use of antithrombin in extracorporeal membrane oxidation | |
| WO2014193800A3 (en) | Aptamers for the treatment of sickle cell disease | |
| PL2832240T3 (pl) | Sposób zmniejszania zawartości sacharydów w koncentratach soków | |
| MX362111B (es) | Un metodo para mejorar la funcion hepatica. | |
| SG10201807066UA (en) | Peptides and methods of use | |
| FR3010432B1 (fr) | Structure de securite, du genre echafaudage, pour le travail en elevation |